PMID- 2835055
OWN - NLM
STAT- MEDLINE
DCOM- 19880602
LR  - 20041117
IS  - 0004-4172 (Print)
IS  - 0004-4172 (Linking)
VI  - 38
IP  - 1
DP  - 1988 Jan
TI  - Antithrombotic defense during the postoperative period. Clinical documentation of 
      low molecular weight heparin.
PG  - 120-3
AB  - The incidence of postoperative thromboembolic complications depends on the type 
      of basic disease, the surgical procedure as well as on various additional risk 
      factors. Without perioperative prophylaxis about 10 to 70% of the patients 
      develop deep vein thrombosis (DVT). After an extensive description of different 
      methods to diagnose DVT, the practical use of the radiofibrinogen uptake test is 
      illustrated by means of a clinical trial on low molecular weight heparin (LMWH). 
      The study consisted in a randomized comparative trial on the peri-/postoperative 
      thrombotic prophylaxis with LMWH 2,500 U s.c. once daily and unfractionated 
      heparin (UFH) 5,000 U s.c. twice daily. 231 patients were recruited from the 
      field of elective surgery and were characterized by a comparatively high 
      postoperative risk of thrombosis. The medication of heparins was supplemented by 
      dihydroergotamine (DHE) 0.5 mg s.c with the advantage to measure the prophylactic 
      potential of short-chain heparin in comparison with UFH/DHE as a highly active 
      antithrombotic regimen. The duration of prophylaxis with applications at 12- and 
      24-h intervals, respectively, covered a period of at least 7 days. Diagnosis of 
      leg vein thrombosis was performed with the radiofibrinogen uptake test. Under 
      standard prophylaxis with UFH/DHE twice a day 14 patients suffered postoperative 
      thromboses, while with LMWH/DHE once a day only 4 patients suffered thromboses (p 
      less than 0.025). Bleeding complications (wound hematome, re-operations, 
      postoperative blood loss) were equally frequent in both groups and were in the 
      normal range. Other side effects, in particular peripheral vasospasms and anginal 
      attacks, were not observed.
FAU - Welzel, D
AU  - Welzel D
AD  - Pharmacological Department, University of Regensburg, Fed. Rep. of Germany.
FAU - Wolf, H
AU  - Wolf H
FAU - Koppenhagen, K
AU  - Koppenhagen K
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Germany
TA  - Arzneimittelforschung
JT  - Arzneimittel-Forschung
JID - 0372660
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Heparin, Low-Molecular-Weight)
SB  - IM
MH  - Adult
MH  - Female
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Heparin, Low-Molecular-Weight/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Plethysmography, Impedance
MH  - Postoperative Complications/*prevention & control
MH  - Postoperative Period
MH  - Pulmonary Embolism/prevention & control
MH  - Thromboembolism/etiology/*prevention & control
MH  - Ultrasonics
EDAT- 1988/01/01 00:00
MHDA- 1988/01/01 00:01
CRDT- 1988/01/01 00:00
PHST- 1988/01/01 00:00 [pubmed]
PHST- 1988/01/01 00:01 [medline]
PHST- 1988/01/01 00:00 [entrez]
PST - ppublish
SO  - Arzneimittelforschung. 1988 Jan;38(1):120-3.